A Mutated H1N1 Strain Is Hitting Younger Immunity First

Clinical labs found flu in 5.7% of tests in the week ending Oct. 17, and 99.2% of subtyped influenza A viruses were H1N1. National activity is still called low, but the climb started in late August, weeks ahead of a typical U.S. fall.

The strain carrying the season is influenza A(H1N1)pdm09 with a change called G155E. Lab work from Seattle shows that change blunt antibodies most in younger people, after a winter dominated by a different virus.

Flu Tests Hit 5.7% Positive, a Mid-October Record

The Centers for Disease Control and Prevention’s FluView report for Week 41, posted Oct. 23, is the cleanest snapshot of how early this is. Clinical laboratories tested 51,490 specimens and found flu in 2,918 of them. Influenza A made up 97.9% of those positives.

WHERE THE VIRUS STANDS

• Test positivity: 5.7% of flu tests came back positive in the week ending Oct. 17, against less than 1% in the same week last year.
• The subtype: Public health labs subtyped 241 influenza A viruses that week; 239 (99.2%) were H1N1, none were H3N2, and two were H5.
• Clinic traffic: 2.2% of outpatient visits were for flu-like illness, still below the national baseline, with Louisiana and Hawaii the two moderate jurisdictions and none high or very high.
• Hospital load: 4,811 people were admitted with influenza that week in the National Healthcare Safety Network count, and 0.2% of deaths were attributed to flu.

CDC estimates as of Oct. 21 put infections growing, or likely growing, in 44 states. FluSurv-NET logged 798 laboratory-confirmed flu hospitalizations between Oct. 4 and Oct. 17. The weekly rate was 1.1 per 100,000, the same as the week before, and CDC said the delay-adjusted range is 1.5 to 2.0. That is the highest Week 41 hospital rate since the 2010-2011 season. The cumulative rate sat at 2.1 per 100,000. No influenza-associated pediatric deaths had been reported for the 2026-2027 season in that report.

Andrew Pekosz, a virologist at the Johns Hopkins Bloomberg School of Public Health, said cases are still relatively low and the country is in the early phases of a surge. CDC’s own line in FluView was plainer: early-season influenza activity is higher than typically observed at this time of year.

Last Winter’s H3N2 Wave Left an H1N1 Gap

The 2025-2026 season was an H3N2 winter. CDC later modeled at least 32 million illnesses, 380,000 hospitalizations, and 24,000 deaths, with subclade K accounting for most of the typed H3N2. People who were infected then built protection against that family of virus. They did not get a fresh lesson in H1N1.

Dr. Bernard Camins, an infectious-disease physician at the Icahn School of Medicine at Mount Sinai, put the gap in one sentence: even people who got the flu last year are vulnerable. H1N1 is a different virus from the H3N2 that dominated last winter, and the first wave of a season often belongs to whichever strain slips past leftover immunity.

Pekosz described that pattern as the usual one. The first strain that arrives, he said, is the one that escapes immunity the most. When H1N1 started rising in late August, the updated 2026-2027 shots had only just begun to roll out, so a lot of people met the new virus with last winter’s antibodies and last year’s shot, not this year’s.

Who G155E Hits When Antibody Titers Look Strong

H1N1 viruses usually change more slowly than H3N2. This year’s circulating branch is subclade D.3.1.1, one step on from the D.3.1 virus used in the Northern Hemisphere shot. The extra change that virologists keep naming is G155E, sitting in antigenic region Sa on hemagglutinin, a site antibodies use to lock on.

A Fred Hutch and University of Washington team led by Caroline Kikawa and Jesse D. Bloom measured 52,268 neutralization titers from 355 human sera, collected between April and August 2026, against 148 viral strains. Their preprint, posted on bioRxiv, found that D.3.1.1 viruses with Sa changes such as G155E showed reduced neutralization by human sera, with wide differences from person to person. Sera hit hardest tended to come from teenagers and young adults who otherwise had high H1N1 titers.

Individuals who are strongly affected by G155E tend to be younger.

Bloom Lab, Fred Hutch Cancer Center, on X, Sept. 17, 2026

We have measured 47,851 neutralization titers of current human sera vs current influenza strains to inform vaccine update & analyses of viral evolution.

New H1N1 strains (eg, D.3.1.1 + G155E) have reduced neutralization, as do some H3N2 subclade K descendants.…

— Bloom Lab (@jbloom_lab) September 17, 2026

Pekosz said G155E sits at a position known to matter for protective antibody responses, so antibodies from earlier infection or vaccination may not recognize this virus as well. He also said a mismatch is not all-or-nothing. People may have less immunity, not none. CDC, in the same Week 41 report, said it is too early to know which viruses will predominate or what that will mean for vaccine effectiveness.

Alex Greninger, who heads infectious-disease diagnostics at the University of Washington, has said about 98% of the flu samples reaching his lab are H1N1 and that Seattle is already seeing January-level flu in October. The G155E change spread after the strains for this year’s shots were chosen. That is seasonal drift, the same lineage that caused the 2009 pandemic, not a new pandemic virus.

Japan Closed 1,703 Schools as the Virus Moved First

Japan ran this experiment a few months earlier. G155E was detected there in May 2026. The health ministry declared an influenza epidemic on Aug. 28, the second-earliest such call since 1999. U.S. cases began their steady rise in late August and early September, and the Seattle-led serology paper flagged the mutation in mid-September.

HOW G155E GOT A HEAD START

1. February 27, 2026: WHO recommends an A/Missouri/11/2025 (H1N1)pdm09-like virus, a D.3.1 strain, for Northern Hemisphere shots.
2. May 2026: G155E is detected in Japan as D.3.1.1 viruses spread.
3. August 28, 2026: Japan’s health ministry declares an influenza epidemic, the second-earliest since 1999.
4. Late August to early September 2026: U.S. flu indicators begin a steady climb, and the 2026-2027 shots start reaching clinics.
5. September 2026: Seattle-led serology work reports that G155E strains are neutralized more poorly, especially by younger sera.
6. October 5-11, 2026: Japan’s sentinel clinics log 47,746 flu patients, 12.81 per clinic, and 1,703 school and childcare sites close classes or campuses.
7. Week ending October 17, 2026: U.S. clinical-lab positivity reaches 5.7%, with H1N1 at 99.2% of subtyped influenza A.

Japan’s health ministry figures for that October week were about 5.3 times the 9,074 sentinel patients logged in the same week of 2025. Japan’s weekly school closure tallies are the field version of the antibody chart: the virus moved through children and school-age groups first. Pharmacies in the United States have not seen a matching rush for shots. Demand has tracked last year even as the virus arrived early, which means the public calendar has not moved with the lab calendar.

Adults 65 and Older Still Lead U.S. Hospital Stays

The U.S. hospital picture, for now, does not look like a pediatric wave. FluSurv-NET’s Week 41 rates still climb with age at the top of the chart. Among hospitalizations with an influenza A subtype, 112 (98.2%) were H1N1 and two (1.8%) were H3N2.

FLU HOSPITAL RATES BY AGE, WEEK ENDING OCT. 17

Children 0 to 4 already sit third, ahead of working-age adults, which is the usual early-season shape and not proof that G155E has rewritten U.S. risk. It does mean infants and preschoolers are in the mix while school-age rates remain the lowest. A CDC study of 104,969 flu hospitalizations from 2010-2011 through 2018-2019 found that, once people were already in hospital, H1N1 was meaner than H3N2: 42% more likely to go to intensive care, 79% more likely to need a ventilator or ECMO, and 25% more likely to die.

That history is why an H1N1 year is not automatically a mild year for the people who do get sick enough to be admitted. It is also why the younger-antibody finding matters even while adults 65 and older still occupy most of the beds. The groups whose shots and past infections look strongest on paper can still be the groups this mutation sees around.

The Shot Targets a Missouri H1N1 Strain Chosen in February

WHO’s Feb. 27 recommendation set the H1N1 component as an A/Missouri/11/2025 H1N1 vaccine strain. The FDA’s vaccines committee backed that list on March 12, and the agency issued U.S. composition recommendations on March 13. All three components were updated from 2025-2026, including the H3N2 piece chosen to cover last winter’s subclade K virus.

Egg-based shots use A/Missouri/11/2025 (H1N1)pdm09-like, A/Darwin/1454/2025 (H3N2)-like, and B/Tokyo/EIS13-175/2025 (B/Victoria)-like viruses. Cell, recombinant, and nucleic-acid shots swap in A/Darwin/1415/2025 for H3N2 and B/Pennsylvania/14/2025 for influenza B. The H1N1 antigen is D.3.1 in both. Almost all recent human H1N1 sequences are D.3.1.1.

Manufacturers project as many as 135 million flu vaccine doses for the U.S. market. CDC says 100% of that supply is trivalent, 27% is non-egg-based, and 99% is made without thimerosal. Shots are licensed for people 6 months and older.

SHOTS ON THE SHELF THIS SEASON

• Standard three-strain shots: The workhorse option at most pharmacies and clinics, built on the Missouri H1N1, Darwin H3N2, and Victoria B strains.
• High-dose shots: Made for older adults, who still have the highest U.S. hospital rate at 7.4 per 100,000 this week.
• Nasal mist: A needle-free option for people who qualify, useful in pediatric clinics if families will actually show up.
• The new mRNA flu vaccine: One of the non-egg products in the 27% share, with a shorter manufacturing path than eggs if strains keep moving after February.

Pekosz’s point on mismatch still holds for people staring at G155E: the shot is not a miss or a hit. It may cover H1N1 less well than a perfect match, and it still covers H3N2 and influenza B, which have barely shown up. Last winter’s influenza B wave peaked in March 2026. A second strain later in the season is a live possibility, not a theory from nowhere.

Halloween Arrives Before Most Shots Have Kicked In

CDC’s advice for most people is to get vaccinated in September or October. Pekosz’s timing note is sharper this year. Immunity takes about two weeks to reach protective levels, and the season is already moving. A shot given in late October still helps. It simply starts working after a lot of H1N1 has already had a head start.

If a test is positive, prescription antivirals can shorten the illness, and they work best when started within 48 hours of the first symptoms. Camins and Pekosz both flag that window for people 65 and older, children under 5, and anyone with a weak immune system. Those drugs are not on pharmacy shelves without a clinician’s order.

Camins said it is too soon to know how bad this winter will be, only that it is starting earlier. An early start is not a verdict on severity. The open question is narrower than that: the people whose antibodies look excellent against last year’s H1N1 are the same people G155E is best at slipping past, and Halloween on Oct. 31 will land before a late October shot has had its two weeks.

Disclaimer: This article is news reporting and analysis of CDC surveillance, vaccine composition documents, and published serology. It is for information only and is not medical advice, a diagnosis, or a recommendation of any specific flu shot, antiviral, or treatment plan. Readers should talk with a physician, pediatrician, or pharmacist about which vaccine they should get, whether antivirals are appropriate, and how to time a shot around other health conditions. Figures, activity levels, and strain shares reflect the sources cited, including CDC FluView for the week ending Oct. 17, 2026, and may change as later weeks are reported.